Skip to main content
Erschienen in: Reactions Weekly 1/2016

01.07.2016 | Case report

Gemcitabine

Haemolytic uraemic syndrome: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (FDA MedWatch definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * requires intervention to prevent permanent impairment or damage
Literatur
Zurück zum Zitat Ritchie GE, et al. Rituximab to treat gemcitabine induced hemolytic uraemic syndrome in three patients with pancreatic adnenocarcinoma. Asia-Pacific Journal of Clinical Oncology 11 (Suppl. 3): 63, Aug 2015. Available from: URL: http://doi.org/10.1111/ajco.12398 [abstract] - Australia Ritchie GE, et al. Rituximab to treat gemcitabine induced hemolytic uraemic syndrome in three patients with pancreatic adnenocarcinoma. Asia-Pacific Journal of Clinical Oncology 11 (Suppl. 3): 63, Aug 2015. Available from: URL: http://​doi.​org/​10.​1111/​ajco.​12398 [abstract] - Australia
Metadaten
Titel
Gemcitabine
Haemolytic uraemic syndrome: 3 case reports
Publikationsdatum
01.07.2016
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2016
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-016-19849-4

Weitere Artikel der Ausgabe 1/2016

Reactions Weekly 1/2016 Zur Ausgabe

Case report

Paliperidone

Case report

Mefloquine

Case report

Lidocaine

Case report

Binimetinib